Figure 4.

Fibrosis Is Reduced by CXCL12

Fibrosis scorings of uterine tissues in the eight groups with supplemental bone marrow (BM) transplantation at 3 weeks after Asherman’s syndrome modeling. AS increased fibrosis, whereas CXCL12 reduced fibrosis in AS. AMD3100 reversed the effects of endogenous or supplemental CXCL12 administration. *p < 0.01 versus Sham plus BM plus PBS; ^#p < 0.05 versus AS plus BM plus PBS; ^†p < 0.01 versus AS plus BM plus CXCL12.